Basic Information
Cibinqo
Regulatory Information
EMEA/H/C/005452
Authorised
December 9, 2021
October 14, 2021
14
October 30, 2024
Company Information
Belgium
Boulevard de la Plaine 17 1050 Bruxelles
Pfizer Europe MA EEIG
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
Overview Summary
Cibinqo is a medicine used to treat adults and adolescents from 12 years of age with moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry). It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient. Cibinqo contains the active substance abrocitinib.